antihcv
aryl
diketoacid
adk
good
metal
chelat
anticip
adk
might
serv
potenti
inhibitor
sar
cov
scv
ntpasehelicas
hel
mimick
bind
mode
bismuth
complex
effect
compet
zn
ion
bind
site
scv
hel
therebi
disrupt
inhibit
ntpase
helicas
activ
phosphat
releas
assay
fretbas
assay
adk
analogu
show
adk
select
inhibit
duplex
dnaunwind
activ
without
signific
impact
helicas
atpas
activ
also
antivir
activ
adk
shown
depend
upon
substitu
taken
togeth
result
suggest
might
adkspecif
bind
site
scv
hel
warrant
investig
divers
adk
provid
valuabl
insight
ration
design
specif
scv
hel
inhibitor
viral
helicas
coupl
energi
nucleotid
triphosph
ntp
hydrolysi
unwind
duplex
viral
nucleic
acid
drug
target
viral
helicas
current
test
treatment
herp
simplex
viru
hsv
hepat
c
viru
hcv
infect
previou
studi
scv
life
cycl
demonstr
scv
ntpasehelicas
scv
hel
also
like
attract
target
antiscv
therapi
cysteinerich
metal
bind
domain
mbd
locat
n
terminu
scv
hel
known
bind
zn
ion
scv
hel
mbd
essenti
enzymat
activ
viral
viabil
recent
yang
et
al
report
bismuth
complex
effect
compet
zn
ion
bind
site
therebi
disrupt
inhibit
ntpase
helicas
activ
aryl
diketoacid
adk
known
inhibit
sever
viral
target
enzym
integras
hcv
rnadepend
rna
polymeras
rdrp
sequestr
activ
site
metal
previous
also
shown
potent
inhibit
hcv
rdrp
ic
lm
sever
novel
adk
analogu
fig
thu
interest
test
novel
adk
analogu
could
serv
potenti
inhibitor
scv
hel
mimick
bind
mode
bismuth
complex
mbd
synthes
adk
well
clone
purif
scv
hel
perform
previous
describ
inhibit
adk
scv
hel
atpas
activ
measur
phosphat
releas
assay
phosphat
releas
atp
hydrolysi
scv
hel
measur
colorimetr
method
base
complex
format
malachit
green
molybd
ammg
reagent
briefli
solut
scv
helicas
nm
mm
trishcl
ph
buffer
ad
well
assay
plate
alreadi
contain
variou
concentr
chemic
compound
incub
min
rt
reaction
start
ad
reaction
solut
mm
trishcl
ph
mm
nacl
mm
mgcl
mm
atp
nm
circular
ssdna
well
incub
min
reaction
stop
ad
ammg
reagent
malachit
green
ammonium
molybd
tween
hcl
color
see
front
matter
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
b
c
l
develop
min
rt
absorb
nm
measur
amount
phosphat
releas
quantit
use
inorgan
phosphat
standard
curv
experi
repeat
three
time
averag
shown
figur
tabl
adk
investig
studi
show
signific
inhibit
activ
enzym
among
exhibit
moder
inhibit
activ
helicas
atpas
ic
valu
lm
respect
inhibit
adk
analogu
scv
hel
duplex
dnaunwind
activ
measur
fretbas
assay
previous
describ
result
summar
figur
tabl
similar
helicas
atpas
assay
neither
show
inhibit
helicas
duplex
dnaunwind
activ
even
concentr
lm
inhibitori
activ
margin
lm
respect
howev
three
adk
analogu
show
modest
potent
inhibit
scv
hel
duplex
dnaunwind
activ
ic
valu
lm
compar
previous
report
inhibitor
includ
bismuth
complex
lm
lm
vanillinbananin
lm
worth
note
unlik
bismuth
complex
show
order
inhibit
atpas
duplex
dnaunwind
assay
adk
analogu
show
select
inhibit
duplex
dnaunwind
activ
thu
conceiv
adk
might
mechan
inhibit
differ
bismuth
complex
also
noteworthi
adk
analogu
scv
hel
inhibitor
report
date
structureact
relationship
regiochemistri
well
aromat
substitu
dramat
influenc
antiscv
activ
adk
particular
compound
pararelationship
diketoacid
moieti
och
ar
group
show
antivir
activ
also
chlorin
substitu
termin
aromat
ring
complet
differ
effect
inhibitori
activ
adk
comparison
inhibitori
activ
target
enzym
rare
affect
chlorin
contrari
chlorin
substitut
result
signific
chang
antivir
activ
comparison
unsubstitut
counterpart
taken
togeth
result
suggest
possibl
specif
bind
site
adk
scv
hel
warrant
investig
structur
divers
adk
analogu
antiscv
activ
provid
definit
structureact
relationship
well
possibl
bind
site
summari
antihcv
adk
analogu
show
potent
select
inhibit
scv
helicas
duplex
dnaunwind
activ
helicas
atpas
activ
antiscv
activ
adk
shown
depend
upon
regiochemistri
well
substitu
adk
investig
requir
divers
adk
delin
definit
structureact
relationship
well
adkspecif
bind
site
provid
valuabl
insight
ration
design
specif
scv
hel
inhibitor
aryl
diketoacid
adk
duplex
dnaunwind
activ
b
r
c
antihcv
aryl
diketoacid
adk
good
metal
chelat
anticip
adk
might
serv
potenti
inhibitor
sar
cov
scv
ntpasehelicas
hel
mimick
bind
mode
bismuth
complex
effect
compet
zn
ion
bind
site
scv
hel
therebi
disrupt
inhibit
ntpase
helicas
activ
phosphat
releas
assay
fretbas
assay
adk
analogu
show
adk
select
inhibit
duplex
dnaunwind
activ
without
signific
impact
helicas
atpas
activ
also
antivir
activ
adk
shown
depend
upon
substitu
taken
togeth
result
suggest
might
adkspecif
bind
site
scv
hel
warrant
investig
divers
adk
provid
valuabl
insight
ration
design
specif
scv
hel
inhibitor
elsevi
ltd
right
reserv
viral
helicas
coupl
energi
nucleotid
triphosph
ntp
hydrolysi
unwind
duplex
viral
nucleic
acid
drug
target
viral
helicas
current
test
treatment
herp
simplex
viru
hsv
hepat
c
viru
hcv
infect
previou
studi
scv
life
cycl
demonstr
scv
ntpasehelicas
scv
hel
also
like
attract
target
antiscv
therapi
cysteinerich
metal
bind
domain
mbd
locat
n
terminu
scv
hel
known
bind
zn
ion
scv
hel
mbd
essenti
enzymat
activ
viral
viabil
recent
yang
et
al
report
bismuth
complex
effect
compet
zn
ion
bind
site
therebi
disrupt
inhibit
ntpase
helicas
activ
aryl
diketoacid
adk
known
inhibit
sever
viral
target
enzym
integras
hcv
rnadepend
rna
polymeras
rdrp
sequestr
activ
site
metal
previous
also
shown
potent
inhibit
hcv
rdrp
ic
lm
sever
novel
adk
analogu
fig
thu
interest
test
novel
adk
analogu
could
serv
potenti
inhibitor
scv
hel
mimick
bind
mode
bismuth
complex
mbd
synthes
adk
well
clone
purif
scv
hel
perform
previous
describ
inhibit
adk
scv
hel
atpas
activ
measur
phosphat
releas
assay
phosphat
releas
atp
hydrolysi
scv
hel
measur
colorimetr
method
base
complex
format
malachit
green
molybd
ammg
reagent
briefli
solut
scv
helicas
nm
mm
trishcl
ph
buffer
ad
well
assay
plate
alreadi
contain
variou
concentr
chemic
compound
two
author
contribut
equal
work
develop
min
rt
absorb
nm
measur
amount
phosphat
releas
quantit
use
inorgan
phosphat
standard
curv
experi
repeat
three
time
averag
shown
figur
tabl
adk
investig
studi
show
signific
inhibit
activ
enzym
among
exhibit
moder
inhibit
activ
helicas
atpas
ic
valu
lm
respect
inhibit
adk
analogu
scv
hel
duplex
dnaunwind
activ
measur
fretbas
assay
previous
describ
result
summar
figur
tabl
similar
helicas
atpas
assay
neither
show
inhibit
helicas
duplex
dnaunwind
activ
even
concentr
lm
inhibitori
activ
margin
lm
respect
howev
three
adk
analogu
show
modest
potent
inhibit
scv
hel
duplex
dnaunwind
activ
ic
valu
lm
compar
previous
report
inhibitor
includ
bismuth
complex
lm
lm
vanillinbananin
lm
worth
note
unlik
bismuth
complex
show
order
inhibit
atpas
duplex
dnaunwind
assay
adk
analogu
show
select
inhibit
duplex
dnaunwind
activ
thu
conceiv
adk
might
mechan
inhibit
differ
bismuth
complex
also
noteworthi
adk
analogu
scv
hel
inhibitor
report
date
structureact
relationship
regiochemistri
well
aromat
substitu
dramat
influenc
antiscv
activ
adk
particular
compound
pararelationship
diketoacid
moieti
och
ar
group
show
antivir
activ
also
chlorin
substitu
termin
aromat
ring
complet
differ
effect
inhibitori
activ
adk
comparison
inhibitori
activ
target
enzym
rare
affect
chlorin
contrari
chlorin
substitut
result
signific
chang
antivir
activ
comparison
unsubstitut
counterpart
taken
togeth
result
suggest
possibl
specif
bind
site
adk
scv
hel
warrant
investig
structur
divers
adk
analogu
antiscv
activ
provid
definit
structureact
relationship
well
possibl
bind
site
summari
antihcv
adk
analogu
show
potent
select
inhibit
scv
helicas
duplex
dnaunwind
activ
helicas
atpas
activ
antiscv
activ
adk
shown
depend
upon
regiochemistri
well
substitu
adk
investig
requir
divers
adk
delin
definit
structureact
relationship
well
adkspecif
bind
site
provid
valuabl
insight
ration
design
specif
scv
hel
inhibitor
